Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Feb 27, 2019 08:20AM MeiraGTx Holdings plc (MGTX) Reports $80 Million Private Placement of Ordinary Shares
Feb 27, 2019 08:15AM MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
Feb 27, 2019 08:15AM MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
Feb 22, 2019 05:15PM Sinovac Determines Trigger Event Occurred Under Rights Agreement
Feb 21, 2019 05:13PM Form SC 13G Harpoon Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 20, 2019 05:23PM Form SC 13D Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2019 04:48PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 14, 2019 08:00AM Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Feb 14, 2019 08:00AM Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Feb 13, 2019 06:15AM Form SC 13G/A Insys Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Clovis Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A eHealth, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Deciphera Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Wright Medical Group Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A IMMUNOMEDICS INC Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Inspire Medical Systems, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A Audentes Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A ACHILLION PHARMACEUTICAL Filed by: ORBIMED ADVISORS LLC
Feb 4, 2019 07:00AM Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
Jan 23, 2019 05:59PM Form 4 ALPINE IMMUNE SCIENCES, For: Jan 18 Filed by: ORBIMED ADVISORS LLC
Jan 23, 2019 05:21PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Jan 18, 2019 07:02AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene (CELG)
Jan 18, 2019 07:00AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
Jan 16, 2019 07:02AM Alpine Immune Sciences (ALPN) Announces $25 Million Private Placement of Common Stock and Warrants
Jan 16, 2019 07:00AM Alpine Immune Sciences Announces $25 Million Private Placement
Dec 20, 2018 11:02AM Form SC 13D Synthorx, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 17, 2018 08:30AM Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management
Dec 13, 2018 06:34PM Form 4 Synthorx, Inc. For: Dec 11 Filed by: ORBIMED ADVISORS LLC
Dec 13, 2018 04:36PM Form 4 Inspire Medical Systems, For: Dec 11 Filed by: ORBIMED ADVISORS LLC
Dec 4, 2018 07:30AM Carnot BioSciences, a Spin off of SmartZyme BioPharma, and Hemoshear Therapeutics Partner to Develop Protein-Based Therapeutics for Rare Metabolic Diseases
Dec 4, 2018 07:30AM Carnot BioSciences, A Spin Off Of SmartZyme BioPharma, And HemoShear Therapeutics Partner To Develop Protein-Based Therapeutics For Rare Metabolic Diseases
Nov 26, 2018 08:33AM ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer
Nov 19, 2018 08:45AM ORIC Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 14, 2018 04:11PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 13, 2018 04:34PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 8, 2018 04:05PM Natera Reports Third Quarter 2018 Financial Results
Nov 6, 2018 09:11AM Investor, Entrepreneur Steven Yecies Joins Mellitus Health Board
Nov 5, 2018 03:50PM Form SC 13D/A Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Nov 1, 2018 04:12PM Form SC 13D LogicBio Therapeutics, Filed by: ORBIMED ADVISORS LLC
Oct 25, 2018 06:29PM Form 4 LogicBio Therapeutics, For: Oct 23 Filed by: OrbiMed Advisors Israel II Ltd
Oct 25, 2018 05:18PM Form SC 13D/A SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
Oct 22, 2018 07:47AM ORIC to Participate at BTIG Biotech Conference
Oct 19, 2018 04:54PM Form 4 SI-BONE, Inc. For: Oct 19 Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed